

- On page 13, line 18, delete "SEQ ID NO: 46 and SEQ ID NO: 47".
On page 37, line 9, after "isoleucine" delete ", as shown in SEQ ID NO: 52".
On page 37, line 13, after "glycine" replace ~~"as shown in SEQ ID NO. 53"~~ with --as shown in SEQ ID NO: 52--.

IN THE CLAIMS

In claim 3, as three times amended, in line 6, after "isoleucine" delete "as shown in SEQ ID NO: 52."

In claim 4, as twice amended, in line 6, replace "53" with -52--.

REMARKS

This Amendment corrects errors in the amendments made on April 26, 1999, in connection with the submission of a substitute Sequence Listing.

The Substitute Sequence Listing identifies 52 sequences and the prior Amendment erroneously referred to 53 sequences.

The present Amendment removes reference to sequence number 53 and correctly identifies sequences in the application according to the Substitute Sequence Listing submitted on April 26, 1999, which is correct.

This Supplemental Amendment also corrects references to SEQ ID Nos: 28, 46 and 47 which were inserted at the wrong lines due to obvious typographical errors in the April 26, 1999, Amendment. No new matter has been added.

Claims 1-16 stand rejected under obviousness-type double patenting over claims 1-2 of U.S. Patent No. 5,320,958 and claims 1-7 of U.S. Patent No. 5,434,070. Terminal Disclaimers are submitted herewith to overcome the rejection.

In view of the foregoing Applicants respectfully submit that the application is in condition for allowance and request that the pending rejections be withdrawn.

Respectfully submitted,

GERARD J. WEISER

Reg. No. 19,763

WEISER & ASSOCIATES, P.C.

Attorneys for Applicants

LAW OFFICES
Weiser & Associates, P.C.
SUITE 500
230 SO. FIFTEENTH ST.
PHILADELPHIA, PA 19102
(215) 675-4332
FACSIMILE (215) 675-4334

Date 6/21/99